Thomas Vines, MD
Pulmonary Disease · Birmingham, ALNPI 1083634281
Payments from drug & device makers
Across 439 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Boehringer Ingelheim$550
- Pfizer$521
- CSL Behring$463
- Electromed, Inc.$308
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,98999%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 122 | $1,676 |
| AstraZeneca | 65 | $1,019 |
| Boehringer Ingelheim | 37 | $550 |
| Pfizer | 34 | $521 |
| CSL Behring | 14 | $463 |
| Electromed, Inc. | 23 | $308 |
| Genentech USA, Inc. | 21 | $269 |
| Insmed, Inc. | 12 | $265 |
| Merck | 16 | $248 |
| Novartis | 11 | $243 |
| Actelion Pharmaceuticals US, Inc. | 14 | $235 |
| Mylan Specialty L.p. | 12 | $224 |
| Sunovion Pharmaceuticals Inc. | 11 | $177 |
| Grifols USA, LLC | 7 | $116 |
| Jazz Pharmaceuticals Inc. | 3 | $95 |
| Philips North America LLC | 3 | $70 |
| Regeneron Healthcare Solutions, Inc. | 4 | $68 |
| Eisai Inc. | 3 | $45 |
| Optinose US, Inc. | 3 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Gilead | 2 | $39 |
| Johnson & Johnson | 3 | $37 |
| Shire North American Group Inc | 2 | $37 |
| Inspire Medical Systems, Inc. | 2 | $33 |
| Harmony Biosciences LLC | 2 | $32 |
| Biofire Diagnostics, LLC | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Amgen | 1 | $20 |
| Olympus America Inc. | 1 | $20 |
| AbbVie | 1 | $19 |
| United Therapeutics Corporation | 1 | $18 |
| Vapotherm Inc | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Pulmonx Corporation | 1 | $16 |
| Sanofi | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hizentra$124
How this compares
$7,049 in reported general payments places this provider in the 60th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 347 | $238,382 |
| Dupixent PenDupilumab | 24 | $88,855 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 70 | $49,119 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 41 | $21,333 |
| Spiriva RespimatTiotropium Bromide | 29 | $20,485 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 22 | $16,932 |
| Arnuity ElliptaFluticasone Furoate | 69 | $14,951 |
| SunosiSolriamfetol Hcl | 14 | $11,578 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $8,664 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $7,951 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 322 | $7,360 |
| Doxepin Hcl | 66 | $6,447 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $6,353 |
| DayvigoLemborexant | 12 | $5,974 |
| Trazodone Hcl | 443 | $4,754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta, Breo Ellipta, Incruse Ellipta | $1,676 | $291,281503 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,019 | $55,47289 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $550 | $37,41751 claims |
| Eisai Inc.Dayvigo | $45 | $5,97412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Birmingham
- Tejaswini KulkarniBirmingham$1.7M
- Bryan GarciaBirmingham$606K
- Veena AntonyBirmingham$327K
- Steven RoweBirmingham$252K
- Derek RussellBirmingham$190K
- Raymond WadeBirmingham$135K
- Joseph Thachuthara-GeorgeBirmingham$126K
- Jennifer TrevorBirmingham$99K
- Peter MorrisBirmingham$94K
- Amanda DenhamBirmingham$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.